Inve India ▾

Sakar Healthcare share price & results

Sakar Healthcare Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

EU/WHO-GMP pharma CDMO in Gujarat making oncology APIs, oral solids, injectables & liquids for 60+ markets

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue87.0 ₹ crore+50.0% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin28.0 %+8.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit11.0 ₹ crore+120.0% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity12.14 %+3.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin8.23 %+7.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)47.55 %+24.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

2 of 4 judged targets kept · 19 open · verdicts reflect calls analysed to Q1 FY27.

Sakar Healthcare Limited management guidance track record on Inve: 23 targets tracked across analysed earnings calls (2 achieved, 2 missed, 19 open).

TargetOriginal wordingSaidLatest callVerdict
EBITDA Margin25% for FY26
Call transcript, Q2 FY26 · 11 Nov 2025		Q2 FY26Q1 FY27:This is a closed promise from a prior fiscal year. The final verdict remains 'achieved'.
Call transcript, Q1 FY27 · 29 Jul 2026		Achieved
Revenue₹280 crores for FY26
Call transcript, Q2 FY26 · 11 Nov 2025		Q2 FY26Q1 FY27:This is a closed promise from a prior fiscal year. The final verdict remains 'missed'.
Call transcript, Q1 FY27 · 29 Jul 2026		Missed
Oncology EBITDA Margin30% EBITDA margin
Call transcript, Q3 FY26 · 11 Feb 2026		Q3 FY26Q1 FY27:Management guided that margins will be 'soon crossing the 30% margin EBITDA' by the end of FY27, strengthening the previously diluted guidance.
Call transcript, Q1 FY27 · 29 Jul 2026		Revised Up

Source: Inve Guidance Tracker for Sakar Healthcare Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Sakar Healthcare Limited's 23 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 20 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹930.3 −4.17% · −₹40.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +161.1% 1Y

₹0.4k₹0.6k₹0.8k₹1.0k₹1.2kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 11 Nov 2025Q3 FY26 — 11 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 29 Jul 2026

1Y: ₹356.35 on 24 Oct 2025 → ₹930.3. High ₹1,188.4 (22 Sept 2026), low ₹353 (29 Oct 2025).

Previous close
₹970.8
Market cap
₹2.2k Cr
52-week range
₹353 – ₹1,188.4
One year
+159.24%
Price to earnings (TTM to Sept 2026)
51.43×
Return on equity (TTM to Sept 2026)
12.14%

Overview

Symbol
NSE:SAKAR
Exchange
NSE
Currency
INR

What Sakar Healthcare Limited does

Based on the company's own presentations, annual report and earnings calls.

Sakar Healthcare is a Gujarat-based, API-integrated pharmaceutical manufacturer that has evolved from a contract manufacturer into a vertically integrated oncology player. It earns through three lines: CDMO/CMO manufacturing services for large multinational and domestic pharma companies, exports of its own branded and generic formulations across regulated and emerging markets, and licensing/technology-transfer of its developed product dossiers to partners. Its EU-GMP and WHO-GMP certified facilities in Gujarat produce oral solids, oral liquids, sterile (liquid and lyophilised) injections and APIs, with a dedicated integrated API-to-finished-dosage oncology unit at Bavla.

Segments

  • CDMO / CMO Services
  • Own Brand Exports
  • Licensing / Product Development
Manufacturing plants
4
Country presence (own-brand exports)
60+ countries
International partner network
75+ partners
Oncology molecules developed
55 (32 dossiers ready for global launch)
Product registrations (Marketing Authorisations)
292+
Dossiers filed (in process)
300+
Founded 2004Headquarters Changodar, Sarkhej-Bavla Highway, Dist. Ahmedabad, GujaratEmployees 342 (FY2024-25) Company website

How the price took the results

close before → close after

Q1 FY27
+0.4%
29 Jul
Q4 FY26
−3.2%
22 May
Q3 FY26
+1.3%
11 Feb
Q2 FY26
+2.2%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sakar Healthcare Limited

Free account: one company. Everything above stays public.

Write why you follow Sakar Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sakar Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.